化学免疫疗法
癌症研究
多西紫杉醇
肿瘤微环境
免疫系统
三阴性乳腺癌
TLR7型
伊米奎莫德
医学
免疫学
乳腺癌
化疗
癌症
免疫疗法
内科学
先天免疫系统
Toll样受体
作者
Jinrong Peng,Qian Yang,Hong Jiang,Yue Wang,Qingya Liu,Yao Xiao,Qian Zhang
出处
期刊:Nano Today
[Elsevier]
日期:2024-02-01
卷期号:54: 102087-102087
标识
DOI:10.1016/j.nantod.2023.102087
摘要
Chemotherapy-based combinational immunomodulation has been developed to inflame the “cold” tumor immune microenvironment (TiME) for enhanced triple-negative breast cancer (TNBC) chemoimmunotherapy. However, the potential of docetaxel-based chemotherapy combined with immunomodulation by TLR7/8 agonists remains undiscovered. Herein, we first constructed micellar docetaxel (DTX-m) and a TLR7/8 nanoagonist suitable for systematic administration, R848 nanoparticles (R848 NPs). By adjusting the administration sequence, the combination of DTX-m and R848 NPs can efficiently inhibit tumor growth in vivo in a rodent triple-negative breast cancer model. The results of a mechanistic study reveal that alternate sequential administration promotes the polarization of macrophages to F4/80+CD11c+ DC-like macrophages and cumulatively promotes the secretion of CXCL10 and proinflammatory cytokines, which boost the recruitment of NK cells and APCs to reinflame the tumor immune microenvironment, further facilitating the recruitment and proliferation of effector T cells and amplifying tumor chemoimmunotherapy. Administration sequence regulates the therapeutic outcome by steering the polarization of macrophage phenotypes.
科研通智能强力驱动
Strongly Powered by AbleSci AI